9 research outputs found
In vivo Antimalarial and Antitrypanosomal Activity of Strychnogucine B, a Bisindole Alkaloid from Strychnos icaja.
Strychnogucine B is a bisindole alkaloid previously isolated from that possesses promising antiplasmodial properties. This compound was synthesized in four steps from (-)-strychnine. As no acute toxicity was observed at the highest tested cumulative dose of 60 mg/kg, its antimalarial activity was determined intraperitoneally at 30 mg/kg/d in a murine model. In the Peters's 4-d suppressive test, this alkaloid suppressed the parasitaemia by almost 36% on day 5 and 60% on day 7 compared to vehicle-treated mice. In addition to this interesting antimalarial activity, it showed moderate antitrypanosomal activity but no activity in an acute model. It was also inactive on promastigotes. This highlights its selective antimalarial efficacy and leads to further investigation to assess its potential as new antimalarial lead compound
Application of a Biocatalytic Strategy for the Preparation of Tiancimycin-Based Antibody–Drug Conjugates Revealing Key Insights into Structure–Activity Relationships
Antibody–drug
conjugates (ADCs) are cancer chemotherapeutics
that utilize a monoclonal antibody (mAb)-based delivery system, a
cytotoxic payload, and a chemical linker. ADC payloads must be strategically
functionalized to allow linker attachment without perturbing the potency
required for ADC efficacy. We previously developed a biocatalytic
system for the precise functionalization of tiancimycin (TNM)-based
payloads. The TNMs are anthraquinone-fused enediynes (AFEs) and have
yet to be translated into the clinic. Herein, we report the translation
of biocatalytically functionalized TNMs into ADCs in combination with
the dual-variable domain (DVD)-mAb platform. The DVD enables both
site-specific conjugation and a plug-and-play modularity for antigen-targeting
specificity. We evaluated three linker chemistries in terms of TNM-based
ADC potency and antigen selectivity, demonstrating a trade-off between
potency and selectivity. This represents the first application of
AFE-based payloads to DVDs for ADC development, a workflow that is
generalizable to further advance AFE-based ADCs for multiple cancer
types
Application of a Biocatalytic Strategy for the Preparation of Tiancimycin-Based Antibody–Drug Conjugates Revealing Key Insights into Structure–Activity Relationships
Antibody–drug
conjugates (ADCs) are cancer chemotherapeutics
that utilize a monoclonal antibody (mAb)-based delivery system, a
cytotoxic payload, and a chemical linker. ADC payloads must be strategically
functionalized to allow linker attachment without perturbing the potency
required for ADC efficacy. We previously developed a biocatalytic
system for the precise functionalization of tiancimycin (TNM)-based
payloads. The TNMs are anthraquinone-fused enediynes (AFEs) and have
yet to be translated into the clinic. Herein, we report the translation
of biocatalytically functionalized TNMs into ADCs in combination with
the dual-variable domain (DVD)-mAb platform. The DVD enables both
site-specific conjugation and a plug-and-play modularity for antigen-targeting
specificity. We evaluated three linker chemistries in terms of TNM-based
ADC potency and antigen selectivity, demonstrating a trade-off between
potency and selectivity. This represents the first application of
AFE-based payloads to DVDs for ADC development, a workflow that is
generalizable to further advance AFE-based ADCs for multiple cancer
types
Synthesis and Biological Evaluation of Pentacyclic Strychnos Alkaloids as Selective Modulators of the ABCC10 (MRP7) Efflux Pump
The selective modulation of ATP-binding
cassette (ABC) efflux pumps
overexpressed in multidrug resistant cancers (MDR) and attendant resensitization
to chemotherapeutic agents represent a promising strategy for treating
cancer. We have synthesized four novel pentacyclic Strychnos alkaloids alstolucines B (<b>2</b>), F (<b>3</b>), and A (<b>5</b>) and <i>N</i>-demethylalstogucine (<b>4</b>), in addition to known Strychnos alkaloid echitamidine (<b>16</b>),
and we evaluated compounds <b>1</b>–<b>5</b> in
biochemical assays with ABCC10 and P-glycoprotein (P-gp). Alstolucines
B (<b>2</b>) and F (<b>3</b>) inhibited ABCC10 ATPase
activity at 12.5 μM without affecting P-gp function; moreover,
they resensitized ABCC10-transfected cell lines to paclitaxel at 10
μM. Altogether, the alstolucines represent promising lead candidates
in the development of modulators of ABCC10 for MDR cancers overexpressing
this pump
Ribosome-Templated AzideAlkyne Cycloadditions: Synthesis of Potent Macrolide Antibiotics by In Situ Click Chemistry
Ribosome-Templated Azide–Alkyne Cycloadditions: Synthesis of Potent Macrolide Antibiotics by In Situ Click Chemistry
Over half of all antibiotics target
the bacterial ribosomenature’s
complex, 2.5 MDa nanomachine responsible for decoding mRNA and synthesizing
proteins. Macrolide antibiotics, exemplified by erythromycin, bind
the 50S subunit with nM affinity and inhibit protein synthesis by
blocking the passage of nascent oligopeptides. Solithromycin (<b>1</b>), a third-generation semisynthetic macrolide discovered
by combinatorial copper-catalyzed click chemistry, was synthesized
in situ by incubating either <i>E. coli</i> 70S ribosomes
or 50S subunits with macrolide-functionalized azide <b>2</b> and 3-ethynylaniline (<b>3</b>) precursors. The ribosome-templated
in situ click method was expanded from a binary reaction (i.e., one
azide and one alkyne) to a six-component reaction (i.e., azide <b>2</b> and five alkynes) and ultimately to a 16-component reaction
(i.e., azide <b>2</b> and 15 alkynes). The extent of triazole
formation correlated with ribosome affinity for the <i>anti</i> (1,4)-regioisomers as revealed by measured <i>K</i><sub>d</sub> values. Computational analysis using the site-identification
by ligand competitive saturation (SILCS) approach indicated that the
relative affinity of the ligands was associated with the alteration
of macrolactone+desosamine-ribosome interactions caused by the different
alkynes. Protein synthesis inhibition experiments confirmed the mechanism
of action. Evaluation of the minimal inhibitory concentrations (MIC)
quantified the potency of the in situ click products and demonstrated
the efficacy of this method in the triaging and prioritization of
potent antibiotics that target the bacterial ribosome. Cell viability
assays in human fibroblasts confirmed <b>2</b> and four analogues
with therapeutic indices for bactericidal activity over in vitro mammalian
cytotoxicity as essentially identical to solithromycin (<b>1</b>)